---
title: "Unicycive Therapeutics, Inc. Q2 2026: Net income $(1.72M), EPS $(0.06) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295651715.md"
description: "Unicycive Therapeutics reported a Q2 2026 net loss of $1.72M, a significant improvement from the prior year's $6.45M loss, with diluted EPS at $(0.06). The company had no product revenue. On June 30, 2026, it received an FDA complete response letter for its OLC resubmission due to manufacturing deficiencies, though safety and efficacy were not questioned. Unicycive raised approximately $34M in H1 2026 via equity sales to support operations and clinical programs for the next 12+ months."
datetime: "2026-08-12T10:41:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295651715.md)
  - [en](https://longbridge.com/en/news/295651715.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295651715.md)
generator: "portal-rs"
---

# Unicycive Therapeutics, Inc. Q2 2026: Net income $(1.72M), EPS $(0.06) — 10-Q Summary

Unicycive Therapeutics, Inc. reported results for the quarter ended June 30, 2026, posting net income of $(1.72M), a significant improvement from a net loss of $(6.45M) in the year‑ago quarter; diluted EPS was $(0.06) versus $(0.52) in Q2 2025. The company did not report product revenue for the periods presented.

**Financial Highlights**

-   Net income was $(1.72M) for Q2 2026 (three months ended June 30, 2026), improved vs. $(6.45M) in the year‑ago quarter — ~73% improvement YoY.
-   Diluted earnings per share was $(0.06) for Q2 2026, versus $(0.52) in the year‑ago quarter.
-   Revenue: Not reported for the periods presented in Part I, Item 1 (no product sales disclosed).

**Business Highlights**

-   Regulatory: The company received an FDA complete response letter (CRL) for its OLC resubmission on June 30, 2026; the CRL cited a manufacturing deficiency while raising no safety or efficacy concerns.
-   Clinical and development: UNI-494 Phase I completed in 2024; Unicycive continues to advance programs focused on hyperphosphatemia and acute kidney injury with ongoing development plans.
-   Commercial readiness: The company increased commercial launch preparations and related G&A spending and is preparing supply chain and CMO engagements in anticipation of potential future launches.
-   Funding and liquidity: Unicycive raised approximately $34M in net proceeds from at‑the‑market equity sales in H1 2026 to support operations and clinical programs for the next 12+ months.

Original SEC Filing: Unicycive Therapeutics, Inc. \[ UNCY \] - 10-Q - Aug. 12, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [UNCY.US](https://longbridge.com/en/quote/UNCY.US.md)

## Related News & Research

- [Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback](https://longbridge.com/en/news/296255704.md)
- [Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia](https://longbridge.com/en/news/296044732.md)
- [Algorhythm Holdings Reports Second Quarter 2026 Financial Results](https://longbridge.com/en/news/296124832.md)
- [ZTO Express Q2 2026 Earnings Preview](https://longbridge.com/en/news/296149351.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**